Clinical Trials Logo

Clinical Trial Summary

Acute kidney injury (AKI) is a common and under-diagnosed problem in patients with liver cirrhosis, and is associated with significant illness and preventable death. Blood (serum) creatinine is the current test for kidney function, but it is an insensitive and non-specific marker in cirrhosis. The investigators hypothesise that blood (plasma) levels of kidney injury molecule-1 (KIM-1) will detect AKI earlier and predict the risk of worsening AKI in cirrhosis, thus identifying patients in need of prompt and effective treatment and improving patient outcomes. The investigators will collect blood and urine samples from cirrhosis patients admitted into hospital and study the relationship between plasma KIM-1, other diagnostic 'biomarker' tests that have recently been proposed, and patient outcomes.


Clinical Trial Description

In 2015 the International Club of Ascites redefined AKI in cirrhosis as an increase in serum creatinine (sCr) of 26.5 µmol/L as even small increases in sCr are clinically relevant and associated with poorer outcomes. The investigators recently conducted a ward-based study of 105 cirrhotic patients admitted to the Royal Infirmary of Edinburgh (RIE) Liver Unit over a 3-month period and showed that 40% of patients developed AKI, and incidence of AKI increased with severity of cirrhosis. Increased AKI stage was associated with incrementally longer hospital stay, at an extra cost to the NHS of ~£400/day (data.gov.uk), and a greater mortality. Indeed, the mortality rate for cirrhotic patients without AKI was 6%, compared to 18%, 35% and 50% in patients with AKI stage 1, 2 and 3 respectively.

sCr is a suboptimal marker of renal dysfunction in advanced cirrhosis. Despite a normal sCr, patients may already have significant renal dysfunction, thus rendering sCr a late marker of AKI. Moreover, recurrent mild episodes of AKI, where sCr may not exceed normal laboratory limits, can lead to a gradual deterioration in baseline renal function, increased susceptibility to further acute insults and higher mortality. There is an urgent unmet need for a superior, more sensitive biomarker (a renal equivalent of troponin I (TnI)) to better identify cirrhotic patients who are most at risk of developing AKI, to aid earlier recognition of kidney impairment and allow rapid and targeted treatment. This is especially important because pre-transplant renal dysfunction in patients with cirrhosis is associated with increased morbidity and mortality after liver transplantation.

The urinary biomarkers neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP) and albumin, are significantly higher in cirrhotic patients with acute tubular necrosis (ATN), compared with pre-renal AKI and hepatorenal syndrome (HRS). Additionally, L-FABP is a marker of renal hypoxia and has been identified as a promising marker for early diagnosis of AKI, and for predicting dialysis requirement and in-hospital mortality. In view of the progressive renal vasoconstriction that occurs as cirrhosis advances, L-FABP may be a potentially relevant marker, although increased hepatic release may render it non-specific in the context of acute liver injury.

Plasma KIM-1 is a biomarker that is specific and sensitive for both acute and chronic kidney injury. KIM-1 is a transmembrane glycoprotein that is upregulated in proximal tubular cells during AKI. Work from our Group showed that early measurement of plasma KIM-1 was a more sensitive predictor of patient outcome than sCr in AKI after paracetamol-induced acute liver injury. Furthermore, in a cohort of patients with type-1 diabetes, normal sCr and normo/microalbuminuria, an elevated plasma KIM-1 level was strongly associated with risk of early progressive renal decline. However, plasma KIM-1 has never been evaluated in patients with chronic liver disease.

HYPOTHESES

1. Plasma KIM-1 will be higher in patients with cirrhosis who go on to develop AKI and serve as an earlier predictive marker when compared with sCr.

2. Plasma KIM-1 will be more effective at early identification of AKI than other candidate AKI biomarkers (fractional excretion of sodium (FeNa), protein to creatinine ratio (PCR), urinary L-FABP and urinary KIM-1).

Protocol

Blood and urine samples will be collected on admission and day 2, to assess initial trends (in a similar way to TnI). Measurements will be repeated on day 7 (or at discharge if <7 days) as a potential indicator of unresolved AKI. Final follow-up samples will be taken 30 days after discharge. Plasma will be prepared from whole blood samples according to an established SOP and stored along with urine specimens (using a linked anonymised format) at -800 d.c. in the RIE Clinical Research Facility (RIE CRF). KIM-1 will be measured by microsphere-based Luminex technology, as previously described for human plasma. Urinary L-FABP will be measured by ELISA. Outcome data up to 30 days will be collected from TRAK and case note reviews. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03156426
Study type Observational
Source University of Edinburgh
Contact
Status Completed
Phase
Start date May 15, 2017
Completion date November 15, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A